Novo Holdings

Sparrow Quantum Aps. is a Danish company specializing in quantum technology, particularly in the development of advanced light-matter interfaces. The firm focuses on creating deterministic single-photon sources, which are essential for various quantum technologies. Sparrow Quantum boasts the highest efficiency for on-chip single-photon sources globally, characterized by exceptional photon purity, indistinguishability, and outcoupling capabilities. This cutting-edge technology is rooted in over twenty years of research at the renowned Niels Bohr Institute in Copenhagen, from which the company holds exclusive licenses for key patents. By leveraging self-assembled quantum dots paired with slow-light photonic-crystal waveguides, Sparrow Quantum enhances light-matter interactions, providing critical advancements for its clients in the field of photonic quantum technology.

FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

Oxford Nanopore Technologies is a biotechnology company specializing in nanopore-based sequencing technology for analyzing DNA, RNA, proteins, and small molecules. Its diverse product line includes the portable MinION device, the benchtop PromethION, the GridION system, and Flongle, which caters to on-demand sequencing needs. The technology enables real-time data streaming and is applicable across various fields such as human genomics, cancer research, microbiology, plant science, and environmental studies. Additionally, Oxford Nanopore's products support rapid and accessible molecular analysis, making them suitable for both laboratory and field use. The company's innovations are backed by a robust patent portfolio and are utilized in over 80 countries, addressing needs in healthcare, agriculture, and education. Founded in 2005 and headquartered in Oxford, United Kingdom, Oxford Nanopore also maintains offices in several other countries, enhancing its global reach in advancing genomic research and applications.

Single Use Support GmbH, founded in 2015 and headquartered in Kufstein, Austria, specializes in manufacturing heavy-duty single-use plastic containers and packaging products for the transportation of liquids, primarily serving the biopharma industry. The company develops innovative bulk filling systems, including BULK.STREAM and RoSS.FILL, designed to enhance fluid logistics processes and prevent losses due to leakages or bio-contamination. By offering tailored packaging solutions, Single Use Support aims to improve the efficiency and safety of liquid logistics in the pharmaceuticals sector.

Commit Biologics is a biotechnology research company developing a novel immunotherapy platform for the treatment of cancer. The company was founded in 2021 and is headquartered in Aarhus, Denmark.

Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

AMSilk GmbH, founded in 2008 and based in Munich, Germany, specializes in producing spider silk proteins and other biomaterials for various industrial applications. The company offers a range of products, including BioShield-S1, a non-immunogenic spider silk film for protective coatings, and biosteel spider silk fibers. Additionally, AMSilk provides wound care products such as SanaSilk, designed to protect the skin, and spider silk-based solutions for surgical applications. Their product portfolio also includes spider silk protein beads and coatings for medical technology, as well as nonwovens for use in filters, wound dressings, and specialty textiles. AMSilk serves multiple sectors, including pharmaceuticals, cosmetics, and technical textiles, and has established a strategic partnership with Gruschwitz Textilwerke AG. The company employs a patented biotechnological process to create biodegradable polymers from silk proteins, enabling the production of various forms such as powders, hydrogels, and fibers that are environmentally friendly.

FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.

Chromologics is a Danish biotechnology company that specializes in the development of innovative natural food colorants. Originating as a spin-out from the Technical University of Denmark, the company utilizes a fermentation-derived platform to produce novel, sustainable color pigments. These colorants are designed to be stable across various pH levels and temperatures, making them suitable for a wide range of food applications. By offering a bio-based alternative to traditional colorants like carmine, Chromologics aims to support food producers in creating more natural products while enhancing the color of their offerings.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

Biomason is a company focused on developing biological cement-based building materials that offer a sustainable alternative to traditional clay and concrete. By utilizing natural microorganisms and innovative chemical processes, Biomason produces biocement at ambient temperatures, significantly reducing the energy consumption typically associated with conventional manufacturing methods. This technology not only provides builders with carbon-free building materials but also aims to eliminate 25% of the concrete industry's global carbon emissions by 2030. Since its inception in 2012, Biomason has successfully implemented its biocement in various projects across the United States and Europe, with its bioLITH precast tile products currently available for commercial use.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Chromologics is a Danish biotechnology company that specializes in the development of innovative natural food colorants. Originating as a spin-out from the Technical University of Denmark, the company utilizes a fermentation-derived platform to produce novel, sustainable color pigments. These colorants are designed to be stable across various pH levels and temperatures, making them suitable for a wide range of food applications. By offering a bio-based alternative to traditional colorants like carmine, Chromologics aims to support food producers in creating more natural products while enhancing the color of their offerings.

AMSilk GmbH, founded in 2008 and based in Munich, Germany, specializes in producing spider silk proteins and other biomaterials for various industrial applications. The company offers a range of products, including BioShield-S1, a non-immunogenic spider silk film for protective coatings, and biosteel spider silk fibers. Additionally, AMSilk provides wound care products such as SanaSilk, designed to protect the skin, and spider silk-based solutions for surgical applications. Their product portfolio also includes spider silk protein beads and coatings for medical technology, as well as nonwovens for use in filters, wound dressings, and specialty textiles. AMSilk serves multiple sectors, including pharmaceuticals, cosmetics, and technical textiles, and has established a strategic partnership with Gruschwitz Textilwerke AG. The company employs a patented biotechnological process to create biodegradable polymers from silk proteins, enabling the production of various forms such as powders, hydrogels, and fibers that are environmentally friendly.

Deep Branch Biotechnology Ltd., founded in 2018 and based in Nottingham, UK, specializes in carbon recycling services aimed at creating sustainable ingredients for food and feed. By utilizing clean and renewable carbon and energy sources, the company employs a proprietary gas fermentation platform that leverages sustainable feedstocks to produce bio-based products with a significantly reduced carbon footprint. Deep Branch focuses on customer-driven research and development, enabling it to swiftly deliver innovative solutions to meet the growing demand for sustainable food systems. The company collaborates with local suppliers of strategic raw materials, fostering local economies while ensuring a reliable input supply. With a clear roadmap for scaling its operations, Deep Branch has formed strong partnerships across the value chain and has integrated effectively with carbon dioxide suppliers to optimize the deployment of its technology. By producing ingredients that require no arable land and minimal water, Deep Branch is addressing climate change and biodiversity loss, contributing to a more sustainable future without compromising on nutritional quality.

ZELP Ltd. is a London-based company founded in 2017 that specializes in manufacturing a wearable device aimed at reducing methane emissions from livestock. The device works by oxidizing methane into carbon dioxide and includes features such as geolocation, heat detection, early disease detection, and emission frequency monitoring. By providing farmers with tools to measure the volume of oxidized methane, ZELP seeks to significantly mitigate the environmental impact of livestock farming, contributing to more sustainable agricultural practices.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

The Protein Brewery B.V., founded in 2019 and based in Breda, the Netherlands, specializes in the development, manufacture, and commercialization of sustainable animal-free proteins. The company focuses on producing Fermotein, a fungi-based protein created through advanced fermentation technologies. This innovative approach enables the company to utilize significantly less land and water compared to traditional animal protein production methods, while still delivering high yields and maintaining taste and nutritional quality. The Protein Brewery aims to provide consumers with protein-integrated foods that contain essential amino acids, vitamins, and minerals necessary for a healthy and balanced diet.

Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, founded in 2016. The company specializes in developing proprietary bispecific antibodies aimed at engaging gamma-delta T cells for the treatment of both hematological and solid cancers. Its innovative platform, known as the Gammabody platform, is designed to create next-generation bispecific antibodies that activate the immune system to recognize and eliminate tumor cells. By harnessing the potential of γδ T cells, Lava Therapeutics aims to produce potent, safe, and cost-effective biopharmaceuticals that enhance the body's ability to combat cancer, thereby transforming the landscape of cancer treatment.

Chromologics is a Danish biotechnology company that specializes in the development of innovative natural food colorants. Originating as a spin-out from the Technical University of Denmark, the company utilizes a fermentation-derived platform to produce novel, sustainable color pigments. These colorants are designed to be stable across various pH levels and temperatures, making them suitable for a wide range of food applications. By offering a bio-based alternative to traditional colorants like carmine, Chromologics aims to support food producers in creating more natural products while enhancing the color of their offerings.

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

Reapplix ApS, founded in 2008 and based in Birkerod, Denmark, is a research and development company focused on improving wound healing through the use of blood-derived proteins. The company identifies and isolates these proteins to create a tissue regeneration device that provides biological treatment for chronic wounds, particularly diabetic foot ulcers. By utilizing a platform that delivers evidence-based biological wound therapy made entirely from a patient's own blood, Reapplix enables hospitals to offer autologous active cell therapy. This approach allows patients to leverage their own biological materials for enhanced healing outcomes.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for acute and chronic liver diseases. The company's therapeutic approach is centered on a proprietary molecular target known as mitogen-activated protein kinase 4 (MKK4), identified as a crucial regulator of liver regeneration through research by Professor Lars Zender and his team at the University Hospital Tübingen. HepaRegeniX aims to create small-molecule inhibitors of MKK4 that can enhance the regenerative capacity of hepatocytes, even in severely diseased livers. This research has significant implications for treating various liver disorders, including nonalcoholic steatohepatitis.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in developing innovative treatments for severe rare diseases with significant unmet medical needs. Its primary product candidate, Apraglutide, is a long-acting synthetic analog of glucagon-like peptide-2 (GLP-2) designed to enhance the intestine's ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support. VectivBio aims to deliver transformational therapies that significantly improve the lives of patients and their families, rather than offering only incremental benefits over existing treatments.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Clario delivers the endpoint technology solutions for clinical trials. Clario fuses scientific expertise and global scale into the broadest endpoint technology platform to enable pharmaceutical, biotech and medical device partners to transform lives. Through Trial Anywhere™, Clario has mastered the ability to generate rich evidence across all trial models: decentralized, hybrid and site-based clinical trials. With 30 facilities in nine countries across North America, Europe and Asia Pacific, Clario's global team of science, technology and operational experts has been delivering the richest clinical evidence for nearly 50 years.

Reapplix ApS, founded in 2008 and based in Birkerod, Denmark, is a research and development company focused on improving wound healing through the use of blood-derived proteins. The company identifies and isolates these proteins to create a tissue regeneration device that provides biological treatment for chronic wounds, particularly diabetic foot ulcers. By utilizing a platform that delivers evidence-based biological wound therapy made entirely from a patient's own blood, Reapplix enables hospitals to offer autologous active cell therapy. This approach allows patients to leverage their own biological materials for enhanced healing outcomes.

Stipe Therapeutics, founded in 2018 and based in Aarhus C, Denmark, develops peptide therapeutics aimed at eliminating tumors and cancer. The company focuses on harnessing the innate immune system to combat cancer by creating first-in-class drugs that target intracellular protein-protein interactions within the STING Pathway. This pathway is a crucial driver of innate immunity and plays a significant role in regulating tumorigenesis and autoimmune disorders. Stipe Therapeutics has successfully identified and validated compounds that sensitize the STING pathway, enabling modulation of the tumor microenvironment to promote a robust anti-tumoral response.

Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company focuses on the tissue-specific regulation of sex hormone effects to address various urological and endocrinological diseases. Its key products include Fispemifene, a selective estrogen receptor modulator designed to treat symptoms of low testosterone in men, and a 17HSD1-inhibitor targeting endometriosis. Forendo Pharma aims to enhance treatment options for both men's and women's health by developing innovative therapies that address unmet medical needs in gynecological conditions, such as endometriosis and polycystic ovarian syndrome.

Oxford BioMedica is a biopharmaceutical company based in Oxford, United Kingdom, specializing in gene and cell therapy. It is recognized for its expertise in lentiviral vector technology, which allows for the integration of therapeutic genes into non-dividing cells, including neurons and retinal cells. The company operates in two main segments: Platform and Product. The Platform segment focuses on bioprocessing and development services for third parties, while the Product segment is dedicated to the clinical and preclinical development of gene and cell therapies targeting a range of diseases, particularly those affecting the ocular and central nervous system. Oxford BioMedica's product pipeline includes several candidates, such as OXB-302 for haematological tumors and OXB-203 for wet age-related macular degeneration, among others. The company has established partnerships with major pharmaceutical firms, including Novartis and Bristol Myers Squibb, to enhance its research and development efforts. Founded in 1995, Oxford BioMedica aims to transform treatment options for diseases with limited or no existing therapies.

Oxford BioMedica is a biopharmaceutical company based in Oxford, United Kingdom, specializing in gene and cell therapy. It is recognized for its expertise in lentiviral vector technology, which allows for the integration of therapeutic genes into non-dividing cells, including neurons and retinal cells. The company operates in two main segments: Platform and Product. The Platform segment focuses on bioprocessing and development services for third parties, while the Product segment is dedicated to the clinical and preclinical development of gene and cell therapies targeting a range of diseases, particularly those affecting the ocular and central nervous system. Oxford BioMedica's product pipeline includes several candidates, such as OXB-302 for haematological tumors and OXB-203 for wet age-related macular degeneration, among others. The company has established partnerships with major pharmaceutical firms, including Novartis and Bristol Myers Squibb, to enhance its research and development efforts. Founded in 1995, Oxford BioMedica aims to transform treatment options for diseases with limited or no existing therapies.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

Envirotainer AB specializes in the production, development, and rental of active temperature-controlled containers designed for the air transportation of temperature-sensitive healthcare products. Established in 1986 and headquartered in Upplands Väsby, Sweden, the company operates internationally with facilities in major locations such as Singapore, Dallas, Frankfurt, and Toronto, along with a network station in Hyderabad. Envirotainer serves a diverse clientele, including pharmaceutical and biotech companies, by offering a comprehensive suite of services that encompasses laboratory testing, qualification, validation support, and training through the Qualified Envirotainer Program. With over 30 years of experience, Envirotainer has established itself as a leader in secure cold chain solutions, ensuring that pharmaceutical products are transported in a controlled environment to meet the demands of the global market.

Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company focuses on the tissue-specific regulation of sex hormone effects to address various urological and endocrinological diseases. Its key products include Fispemifene, a selective estrogen receptor modulator designed to treat symptoms of low testosterone in men, and a 17HSD1-inhibitor targeting endometriosis. Forendo Pharma aims to enhance treatment options for both men's and women's health by developing innovative therapies that address unmet medical needs in gynecological conditions, such as endometriosis and polycystic ovarian syndrome.

Therachon is a biotechnology company dedicated to developing treatments for rare genetic diseases that currently lack available therapies. Based in Basel, Switzerland, with research facilities in Nice, France, Therachon focuses on creating innovative therapeutics for conditions such as achondroplasia, the most prevalent form of short-limbed dwarfism, through its lead candidate, TA-46. The company also addresses other rare gastrointestinal and musculoskeletal disorders, aiming to provide effective solutions for severe medical conditions like short bowel syndrome.

NBE-Therapeutics GmbH, founded in 2012 and based in Basel, Switzerland, specializes in developing antibody-drug conjugates (ADCs) for cancer treatment. The company is focused on creating innovative therapies that aim to enhance survival rates and improve the quality of life for cancer patients globally. Utilizing a proprietary ADC platform, NBE-Therapeutics develops immune-stimulatory therapies that combine potent anthracycline payloads with targeted delivery to tumor cells. This approach not only aims to directly attack cancer cells but also to elicit a durable immunological response against tumors, positioning the company as a significant player in the biopharmaceutical industry dedicated to cancer care.

Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland.

Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, specializing in the development of biocatalysts for the fermentation of fine chemicals. Established in 2012, the company leverages innovative high-throughput screening technology to create tailored processes that facilitate the efficient production of complex chemical compounds, including flavors, fragrances, active pharmaceutical ingredients, pigments, and additives. By utilizing biocatalysis, Biosyntia aims to significantly reduce production costs and environmental impact compared to traditional chemical synthesis methods. The company collaborates with manufacturers to promote sustainable manufacturing processes, contributing to a greener future in the chemical industry.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists, which are designed to monitor and manage these metabolic conditions by reducing blood flow and lipid uptake in adipose tissue.

Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.

Macrophage Pharma Limited is an immuno-oncology company based in Berkhamsted, United Kingdom, established in 2014. The company specializes in discovering and developing innovative therapies aimed at enhancing anti-tumor immune responses. Its technology platform focuses on the selective delivery of small molecule drugs to tumor-associated macrophages, which activates the body's natural immune system to combat cancer. By harnessing this targeted approach, Macrophage Pharma aims to improve treatment outcomes for patients facing cancer.

HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for acute and chronic liver diseases. The company's therapeutic approach is centered on a proprietary molecular target known as mitogen-activated protein kinase 4 (MKK4), identified as a crucial regulator of liver regeneration through research by Professor Lars Zender and his team at the University Hospital Tübingen. HepaRegeniX aims to create small-molecule inhibitors of MKK4 that can enhance the regenerative capacity of hepatocytes, even in severely diseased livers. This research has significant implications for treating various liver disorders, including nonalcoholic steatohepatitis.

Reapplix ApS, founded in 2008 and based in Birkerod, Denmark, is a research and development company focused on improving wound healing through the use of blood-derived proteins. The company identifies and isolates these proteins to create a tissue regeneration device that provides biological treatment for chronic wounds, particularly diabetic foot ulcers. By utilizing a platform that delivers evidence-based biological wound therapy made entirely from a patient's own blood, Reapplix enables hospitals to offer autologous active cell therapy. This approach allows patients to leverage their own biological materials for enhanced healing outcomes.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

Verona Pharma is a clinical-stage biopharmaceutical company based in London, established in 2005. The company specializes in developing and commercializing therapies for respiratory diseases that have significant unmet medical needs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is being developed in various formulations, including nebulized, dry powder inhaler, and pressurized metered-dose inhaler, with the nebulized form currently in Phase 2b clinical development for the maintenance treatment of COPD. Verona Pharma's commitment is to enhance the health and quality of life for individuals suffering from chronic respiratory conditions through innovative therapeutic solutions.

Clario delivers the endpoint technology solutions for clinical trials. Clario fuses scientific expertise and global scale into the broadest endpoint technology platform to enable pharmaceutical, biotech and medical device partners to transform lives. Through Trial Anywhere™, Clario has mastered the ability to generate rich evidence across all trial models: decentralized, hybrid and site-based clinical trials. With 30 facilities in nine countries across North America, Europe and Asia Pacific, Clario's global team of science, technology and operational experts has been delivering the richest clinical evidence for nearly 50 years.

Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland.

ObsEva SA is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine. ObsEva's main focus is on therapies for preterm labor. ObsEva was founded in November 2012, by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a specialist in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful biopharmaceutical company which was acquired by Gedeon Richter in 2010. André Chollet is specialist in medicinal and pharmaceutical chemistry with more than 30 years of experience in diverse positions in the biopharmaceutical industry, including in Biogen, GSK and Merck Serono. André Chollet was responsible for the preterm labor program at Serono before the acquisition of the company by Merck KGaA.

Kanyos Bio is focused on developing antigen-specific immune tolerance technology aimed at treating type 1 diabetes and celiac disease. Originating from research at the École Polytechnique Fédérale Lausanne in Switzerland, Kanyos collaborates closely with its sister company, Anokion, and Astellas Pharma to advance its therapeutic offerings. The company is dedicated to creating targeted, disease-modifying therapies that specifically inhibit the immune cells responsible for damage in these conditions, while preserving other immune functions. This precise approach aims to enhance the effectiveness of treatment for patients, potentially leading to better health outcomes.

Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, specializing in the development of biocatalysts for the fermentation of fine chemicals. Established in 2012, the company leverages innovative high-throughput screening technology to create tailored processes that facilitate the efficient production of complex chemical compounds, including flavors, fragrances, active pharmaceutical ingredients, pigments, and additives. By utilizing biocatalysis, Biosyntia aims to significantly reduce production costs and environmental impact compared to traditional chemical synthesis methods. The company collaborates with manufacturers to promote sustainable manufacturing processes, contributing to a greener future in the chemical industry.

Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.

Glionova AB is a development stage biopharmaceutical company based in Stockholm, Sweden, founded in 2014. The company focuses on developing therapies for challenging cancers, particularly glioblastoma, which is a common and aggressive primary brain tumor. Glionova is advancing its lead product, GLN-1001, an orally bioavailable small molecule designed to induce selective cell death in glioblastoma cells while sparing normal brain tissue. In addition to its research and development efforts, Glionova aims to market its product through strategic partnerships with global pharmaceutical companies that specialize in oncology.

Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company focuses on the tissue-specific regulation of sex hormone effects to address various urological and endocrinological diseases. Its key products include Fispemifene, a selective estrogen receptor modulator designed to treat symptoms of low testosterone in men, and a 17HSD1-inhibitor targeting endometriosis. Forendo Pharma aims to enhance treatment options for both men's and women's health by developing innovative therapies that address unmet medical needs in gynecological conditions, such as endometriosis and polycystic ovarian syndrome.

Adaptimmune is a clinical-stage biopharmaceutical company based in Abingdon, United Kingdom, established in 2007. The company specializes in the development of T cell therapies aimed at treating cancer, human immunodeficiency virus, and infectious diseases. Adaptimmune employs a proprietary platform to identify cancer targets, genetically engineer T-cell receptors, and produce therapeutic candidates for patient administration. Its key programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell therapy, and CD70, among others, focusing primarily on solid tumors. By utilizing affinity T cell receptor proteins, Adaptimmune enhances the ability of patient T cells to target and destroy cancerous or infected cells.

Pulmologix AB is a Swedish private clinical stage company founded in 2006 and based in Stockholm. The company focuses on developing, manufacturing, and selling an oral non-steroidal anti-asthmatic drug specifically for the treatment of early onset allergic asthma. Pulmologix is dedicated to exploring innovative medical approaches to address respiratory diseases, contributing to advancements in asthma treatment.

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

Acacia Pharma Ltd. is a pharmaceutical company based in Cambridge, United Kingdom, dedicated to discovering and developing supportive care drugs primarily for cancer patients. The company’s product portfolio features APD405, an injectable formulation aimed at treating nausea and vomiting, APD209 for cancer cachexia, and APD421, an intravenous formulation for preventing and treating nausea and vomiting. Acacia Pharma also focuses on addressing cancer-related issues such as fatigue and xerostomia. Incorporated in 2006, Acacia Pharma aims to enhance the quality of care for patients undergoing medical treatments, including surgery and chemotherapy.

ObsEva SA is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine. ObsEva's main focus is on therapies for preterm labor. ObsEva was founded in November 2012, by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a specialist in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful biopharmaceutical company which was acquired by Gedeon Richter in 2010. André Chollet is specialist in medicinal and pharmaceutical chemistry with more than 30 years of experience in diverse positions in the biopharmaceutical industry, including in Biogen, GSK and Merck Serono. André Chollet was responsible for the preterm labor program at Serono before the acquisition of the company by Merck KGaA.

Avilex Pharma Aps is a biotechnology company based in Copenhagen, Denmark, founded in 2012 as a spin-out from the University of Copenhagen. The company was established by Professor Kristian Strømgaard and Associate Professor Anders Bach, focusing on the development of innovative therapies for various neurological conditions. Avilex Pharma specializes in the creation of dimeric peptides that target PSD95 to address neuropathic pain, as well as the development of inhibitors and neuroprotectants aimed at treating ischemic stroke. By leveraging research from the Department of Drug Design and Pharmacology, the company strives to enhance patient recovery and improve treatment outcomes for those affected by these serious medical conditions.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, specializing in the development of neurokinin (NK) receptor antagonists for clinical and preclinical use. Founded in 2012, the company focuses on creating innovative therapies to address conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at treating intense pruritus caused by targeted anti-cancer therapies. In addition to orvepitant, NeRRe's portfolio includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, a Phase I-ready NK-1 antagonist, and NT-432, a clinical candidate. The company's work targets common and chronic conditions, offering new treatment options for patients suffering from refractory or unexplained cough and other debilitating symptoms.

Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, focused on developing innovative small molecule drugs for cancer treatment. Established in 2005, the company specializes in orally-active drugs that target specific molecular pathways. Its portfolio includes KA2237, a dual-selective inhibitor of PI3K isoforms p110ß and p110d, aimed at treating both hematological and solid tumors, and KA2507, which targets HDAC6 for PD-L1 expressing tumors. Karus Therapeutics combines targeted therapies with immunotherapeutic activity, enabling effective treatment of a variety of cancers as well as immune and inflammatory disorders.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.

Vantia Ltd is a pharmaceutical company based in Southampton, United Kingdom, focused on developing small molecule drugs that address significant unmet medical needs. Established in 2007, the company has a clinical pipeline that includes VA106483, aimed at treating nocturia, a condition that disrupts sleep due to frequent nighttime urination, and VA111913, designed for dysmenorrhea, which involves painful menstrual cramps caused by abnormal uterine contractions. These conditions affect millions of individuals and represent substantial market opportunities. Vantia's strategy involves advancing its proprietary drug candidates through Phase II clinical testing and seeking commercialization through partnerships, positioning itself to make a meaningful impact in the urology and women's health sectors.

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

F-Star Therapeutics is a clinical-stage biopharmaceutical company focused on creating innovative bispecific antibody therapies aimed at improving cancer treatment. Utilizing its proprietary Modular Antibody Technology, F-Star develops bispecific antibodies that enhance the capabilities of traditional monoclonal antibodies while minimizing production challenges. The company's unique approach allows for the rapid discovery and development of these therapies, which seek to block tumor immune evasion and provide patients with more effective and durable treatment options compared to existing immuno-oncology therapies. Founded in 2006, F-Star has established a solid patent position and has attracted significant investment from leading venture capital firms and strategic corporate partners. The company has also formed alliances with major pharmaceutical companies, allowing it to expand its research and development efforts. With a dedicated team based in Cambridge, UK, F-Star is advancing a pipeline of product candidates that leverage its innovative technology.

HTG Molecular Diagnostics is a commercial-stage life sciences company based in Tucson, Arizona, that specializes in precision medicine through its innovative molecular profiling technology. The company provides a range of products, including instruments, assay kits, and software, which are integrated into the HTG EdgeSeq platform. This platform automates sample processing and allows for the rapid, reliable profiling of numerous molecular targets from minimal biological samples. HTG's offerings include various molecular profiling panels designed for oncology and immuno-oncology applications, among others. The company serves a diverse clientele, including biopharmaceutical companies, academic research institutions, and molecular testing laboratories, distributing its products directly in the United States and Europe, as well as through international distributors. HTG Molecular Diagnostics has established partnerships with industry leaders to enhance its research and development efforts, further solidifying its role in advancing diagnostic applications and translational medicine. The company was founded in 1997 and was previously known as HTG, Inc. before rebranding in 2011.

Adenium Biotech ApS is a Danish biopharmaceutical company founded in 2011 and based in Copenhagen. The company specializes in the development and commercialization of antibiotics aimed at treating multi-drug resistant bacterial infections, particularly those acquired in hospital settings. Its primary focus includes complicated urinary tract infections and hospital or ventilator-acquired pneumonia, which are often caused by resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Adenium Biotech's lead product, Arenicin, is a non-hemolytic antimicrobial peptide derived from lugworms, demonstrating strong efficacy against Gram-negative pathogens. The company operates as a semi-virtual biotech entity, supported by a team of experts and an international scientific advisory board, with the goal of advancing the Arenicin program through clinical development and regulatory filing.

Funxional Therapeutics Ltd. is a pharmaceutical company based in Cambridge, United Kingdom, specializing in the development of innovative therapeutic products. Founded in 2005, the company is focused on a range of product candidates aimed at treating various medical conditions. Key candidates include BN83470, targeting respiratory issues such as asthma, and BN83250, which is being developed for the prevention of surgical adhesion formation and stroke treatment. Additionally, Funxional Therapeutics is advancing FX125L, an orally available small molecule classified as a broad spectrum chemokine inhibitor. The company also has early-stage preclinical programs addressing Alzheimer's disease, autoimmune disorders, pain, and diabetes, showcasing its commitment to addressing diverse healthcare challenges.

Nanoference ApS develops technology that uses nano particles to deliver Sirna molecules directly to the desired part of the body. The company was founded in 2009 and is based in Aarhus, Denmark.

Archimedes Pharma Limited operates as a specialty pharmaceutical company. Its products include Gliadel, for high grade glioma; Zomorph, an oral sustained release morphine product for cancer pain; Nozinan that treats nausea and vomiting in cancer patients; Pabrinex, a formulation of vitamins B and C for alcoholics experiencing acute withdrawal; and Nasalfent, an intranasal fentanyl for relief of cancer pain. The company was founded in 2004 and is headquartered in Reading, the United Kingdom. It has operations in the United Kingdom, France, and Germany.

F-Star Therapeutics is a clinical-stage biopharmaceutical company focused on creating innovative bispecific antibody therapies aimed at improving cancer treatment. Utilizing its proprietary Modular Antibody Technology, F-Star develops bispecific antibodies that enhance the capabilities of traditional monoclonal antibodies while minimizing production challenges. The company's unique approach allows for the rapid discovery and development of these therapies, which seek to block tumor immune evasion and provide patients with more effective and durable treatment options compared to existing immuno-oncology therapies. Founded in 2006, F-Star has established a solid patent position and has attracted significant investment from leading venture capital firms and strategic corporate partners. The company has also formed alliances with major pharmaceutical companies, allowing it to expand its research and development efforts. With a dedicated team based in Cambridge, UK, F-Star is advancing a pipeline of product candidates that leverage its innovative technology.

EpiTherapeutics is dedicated to developing innovative cancer therapies through the exploration of epigenetics, a field advanced by Professor Kristian Helin and his team at the Biotech Research & Innovation Centre at the University of Copenhagen. The company focuses on small-molecule therapies, specifically targeting enzymes that regulate transcription in cancerous cells. EpiTherapeutics has established a library of selective small molecule inhibitors aimed at epigenetic regulation, particularly histone demethylases. Its lead pre-clinical compounds are currently being investigated for their potential effectiveness in treating various forms of cancer.

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

Vantia Ltd is a pharmaceutical company based in Southampton, United Kingdom, focused on developing small molecule drugs that address significant unmet medical needs. Established in 2007, the company has a clinical pipeline that includes VA106483, aimed at treating nocturia, a condition that disrupts sleep due to frequent nighttime urination, and VA111913, designed for dysmenorrhea, which involves painful menstrual cramps caused by abnormal uterine contractions. These conditions affect millions of individuals and represent substantial market opportunities. Vantia's strategy involves advancing its proprietary drug candidates through Phase II clinical testing and seeking commercialization through partnerships, positioning itself to make a meaningful impact in the urology and women's health sectors.

F-Star Therapeutics is a clinical-stage biopharmaceutical company focused on creating innovative bispecific antibody therapies aimed at improving cancer treatment. Utilizing its proprietary Modular Antibody Technology, F-Star develops bispecific antibodies that enhance the capabilities of traditional monoclonal antibodies while minimizing production challenges. The company's unique approach allows for the rapid discovery and development of these therapies, which seek to block tumor immune evasion and provide patients with more effective and durable treatment options compared to existing immuno-oncology therapies. Founded in 2006, F-Star has established a solid patent position and has attracted significant investment from leading venture capital firms and strategic corporate partners. The company has also formed alliances with major pharmaceutical companies, allowing it to expand its research and development efforts. With a dedicated team based in Cambridge, UK, F-Star is advancing a pipeline of product candidates that leverage its innovative technology.

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

Celltrix is a Swedish biotechnology/medical device company focusing on reconstructive cosmetic surgery. Research, development and production are based in Malmö. They plan to launch the first product –Credurance – in 2010. Their product represents a new type of dermal filler. An immediate filling effect is achieved and the surrounding cells are presented to a matrix suitable for cell growth. As the cells grow on and inside the matrix, they produce their own environment, natural collagen, which gradually replaces the matrix — biorestoring.

Funxional Therapeutics Ltd. is a pharmaceutical company based in Cambridge, United Kingdom, specializing in the development of innovative therapeutic products. Founded in 2005, the company is focused on a range of product candidates aimed at treating various medical conditions. Key candidates include BN83470, targeting respiratory issues such as asthma, and BN83250, which is being developed for the prevention of surgical adhesion formation and stroke treatment. Additionally, Funxional Therapeutics is advancing FX125L, an orally available small molecule classified as a broad spectrum chemokine inhibitor. The company also has early-stage preclinical programs addressing Alzheimer's disease, autoimmune disorders, pain, and diabetes, showcasing its commitment to addressing diverse healthcare challenges.

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

Nuevolution is a small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a patented hybrid technology that combines wet chemistry and molecular biology to accelerate drug discovery. This platform facilitates the rapid synthesis and DNA-tagging of over 1 billion diverse small molecule compounds, allowing for efficient screening and identification of potent drug leads. Nuevolution partners with pharmaceutical and biotechnology companies, having established agreements with major firms such as Merck, GlaxoSmithKline, and Novartis. The company is also involved in a joint venture with EpiTherapeutics and ExpreS2ion Biotechnologies to develop small molecule drugs targeting epigenetic factors, supported by a project budget from the Danish High Technology Fund. Nuevolution focuses on developing treatments for oncology and inflammatory diseases and also provides contract research services, generating revenue from multiple countries, including Denmark, Sweden, and the USA. The company is privately owned by several key Scandinavian investors.